◈ PeptideAtlasCONNECTED KNOWLEDGE
THE PEPTIDE REFERENCE

Thymosin alpha-1

Thymosin alpha-1 is an immune-modulating peptide studied in viral hepatitis, sepsis, and other illnesses. Human evidence is condition-specific and mixed. A large phase 3 sepsis trial did not reduce 28-day mortality, and it has no FDA-approved US indication for immune enhancement or long COVID.

Also known as Thymosin α1 · Thymalfasin · Tα1

Research / unapproved useHuman clinical researchImmune system
AI-assisted source review · 2026-10-274 cited sources2 min read

At a glance

Alternate drug nameThymalfasin
Peptide length28 amino acids
Research areasHepatitis and immune dysfunction in critical illness
Large recent studyTESTS phase 3 sepsis trial
US approvalNo FDA-approved indication

Overview

Thymosin alpha-1, also called thymalfasin when manufactured as a medicine, is related to a peptide originally identified in thymic preparations. Research concerns interactions between innate and adaptive immunity rather than a simple increase in all immune activity. Historical hepatitis studies and smaller critical-care trials produced signals that encouraged further investigation. The more recent TESTS sepsis trial is especially important because it was larger, blinded, and placebo controlled. It did not confirm a mortality benefit. Regulatory availability differs across countries, but foreign use does not establish a US-approved product or validate commercial claims for general resilience, anti-aging, or recovery from every viral illness.

Supporting sources [1] [2] [3] [4]

How it works

Proposed actions include modulation of antigen-presenting cells, T-cell responses, and innate immune signaling. The exact therapeutic mechanism is broader and less singular than blocking one receptor on a pathogen. Immune state, disease stage, and accompanying treatment may all influence the effect. A change in an immune marker is therefore not sufficient to show improved survival, viral clearance, or a meaningful reduction in symptoms.

Supporting sources [1] [2] [3] [4]

The larger sepsis trial changed the picture

TESTS randomized 1,106 adults with sepsis, with 1,089 included in the modified intention-to-treat analysis. Mortality at 28 days was similar between thymosin alpha-1 and placebo, without a statistically significant difference. This carries more weight for routine sepsis claims than an isolated positive biomarker result or a small uncontrolled series.

Supporting sources [1]

Earlier findings need their own context

An older hepatitis B trial reported delayed virologic responses in some treated patients. The earlier ETASS sepsis trial suggested a possible mortality signal but had statistical and design limitations. These studies are part of the evidence history; neither establishes that the peptide is broadly effective across infections or that present-day care should be replaced.

Supporting sources [2] [3]

Clinical formulations and compounded products differ

Controlled trials help assess the studied preparation, population, and duration. FDA separately raises concerns about immune reactions and impurity characterization in compounded thymosin alpha-1 and describes insufficient information to fully understand those preparations’ safety. A familiar peptide name does not establish equivalent purity, concentration stability, or risk across suppliers.

Supporting sources [4]

Does immune modulation mean prevention or long-COVID benefit?

No. Changing immune pathways is a mechanism, not an established patient outcome. Evidence from chronic hepatitis or intensive-care sepsis cannot be transferred to prevention, general wellness, or persistent post-viral symptoms without direct trials. Its US regulatory status remains separate from use or authorization in another country.

Supporting sources [1] [2] [4]

Reading this profile

Jurisdiction: United States: no FDA-approved thymosin alpha-1 medicine; foreign authorizations and uses vary by country.. Molecular class: Synthetic N-acetylated 28-amino-acid thymic peptide.

This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.

Sources & references

Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.

  1. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗
    Original research · Checked 2026-10-27
  2. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. ↗
    Original research · Checked 2026-10-27
  3. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. ↗
    Original research · Checked 2026-10-27
  4. FDA — bulk substances with potential significant safety risks ↗
    Regulatory source · Checked 2026-10-27
CONTINUE EXPLORING

Related profiles

Aviptadil ↗Aviptadil is synthetic vasoactive intestinal peptide, a signaling molecule with vascular and immune effects. Major trials did not establish benefit for severe COVID-19 respiratory failure. A combination with phentolamine is licensed for erectile dysfunction in some countries, a different formulation and indication from investigational lung treatment.Cyclosporine ↗Cyclosporine is an established immunosuppressant used in organ transplantation and selected inflammatory diseases. It reduces T-cell activation through calcineurin inhibition. Kidney toxicity, hypertension, infections, malignancy risk, interactions, and important formulation differences make monitoring central to its clinical use.Echinocandins ↗Echinocandins are approved intravenous antifungals that inhibit fungal cell-wall glucan synthesis. The class includes caspofungin, micafungin, anidulafungin, and rezafungin. Indications, age ranges, formulation limits, and exposure differ; they should not be presented as interchangeable treatments for every fungal infection.Enfuvirtide ↗Enfuvirtide is an HIV-1 fusion inhibitor developed for treatment-experienced patients with resistant virus. Used with an optimized antiretroviral regimen, it improved viral suppression in pivotal trials. The US brand Fuzeon was commercially discontinued in February 2025, so historical approval and present availability must be distinguished.LL-37 ↗LL-37 is a human host-defense peptide produced by cleavage of the hCAP18 precursor. It has antimicrobial and immune-signaling activity and has been studied topically for venous leg ulcers. A larger controlled wound trial did not show significant overall healing benefit, and systemic therapeutic use remains unestablished.Motixafortide ↗Motixafortide is an approved stem-cell mobilization medicine used with filgrastim before autologous transplantation in multiple myeloma. It blocks CXCR4 so more hematopoietic stem cells enter the bloodstream for collection. This indication is distinct from experimental attempts to use CXCR4 blockade as cancer treatment.